StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer BeneFIX [legacy through FY24] by Quarter

BeneFIX (coagulation factor IX) [legacy through FY24] — U.S. reported YoY (%) (%)

QuarterlyAnnual

Pfizer BeneFIX [legacy through FY24]: -20.0% in Q4 2024, down 19.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2024
-20.0%
Period ended Dec 31, 2024
Change on a year earlier
-19.0 pts
-1.0% in Q4 2023
History
29 quarters
Since Q4 2017
Sources
29
Documents cited below

Where the Q4 2024 figure comes from

“|| BeneFIX | 87 | 103 | (16%) | (14%) | 43 | 54 | (20%) | 44 | 49 | (11%) | (8%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBeneFIX (coagulation factor IX) [legacy through FY24] — U.S. reported YoY (%) (%)Year on yearSource
Q4 2024Dec 31, 2024-20.0%-19.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 2024-17.0%-20.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 2024-3.0%+10.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-5.0%-1.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2023Dec 31, 2023-1.0%+3.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 20233.0%+4.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 2023-13.0%-21.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 2023-4.0%-7.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 2022-4.0%+7.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2022Oct 2, 2022-1.0%+1.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2022Jul 3, 20228.0%-1.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2022Apr 3, 20223.0%+13.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗
Q4 2021Dec 31, 2021-11.0%+11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
Q3 2021Oct 3, 2021-2.0%+15.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10032021xex99.htm, filed 2021-11-02) ↗
Q2 2021Jul 4, 20219.0%+14.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07042021xex99.htm, filed 2021-07-28) ↗
Q1 2021Apr 4, 2021-10.0%-11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04042021xex99.htm, filed 2021-05-04) ↗

Cite this data

StockData. (2026). Pfizer BeneFIX [legacy through FY24] (%), quarterly Q4 2017–Q4 2024 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/benefix-leg-yoy-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.